Fulvestrant Injection
Product Images NDC 68001-626

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 68001-626). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fulvestrant-fig-1 (Fulvestrant Fig 1)

Instructional illustration showing steps for preparing an intramuscular injection. The image depicts a hand drawing medication from a vial into a syringe, with numbered steps A, B, and C indicating stages of vial and syringe preparation.*

FDA Label Image

Fulvestrant-fig-10 (Fulvestrant Fig 10)

A Kaplan-Meier overall survival probability graph comparing Fulvestrant with palbociclib versus Fulvestrant with placebo over 54 months. The x-axis indicates time in months, and the y-axis shows overall survival probability as a percentage. The number of patients at risk is listed below for each treatment group at various time points.*

FDA Label Image

Fulvestrant-fig-11 (Fulvestrant Fig 11)

A Kaplan-Meier survival curve graph depicting progression-free survival probability (%) over time in months. It compares two groups: patients receiving Fulvestrant plus Abemaciclib versus Fulvestrant plus Placebo, with censored observations marked. The graph includes the number of patients at risk over time for both groups.*

FDA Label Image

Fulvestrant-fig-12 (Fulvestrant Fig 12)

A Kaplan-Meier survival curve graph comparing survival probability (%) over time in months for two groups: Fulvestrant plus Abemaciclib (N=446) and Fulvestrant plus Placebo (N=223). The graph includes censored observations and a table showing the number of patients at risk at specific time points for each group.*

FDA Label Image

Fulvestrant-fig-13 (Fulvestrant Fig 13)

A Kaplan-Meier curve chart showing event-free probability (%) over time (months) comparing two groups: Fulvestrant with Ribociclib (N=484) and Fulvestrant with Placebo (N=242). The chart includes number of patients still at risk at different time points up to 26 months and marks censoring times for both groups.*

FDA Label Image

Fulvestrant-fig-14 (Fulvestrant Fig 14)

A survival curve chart showing event-free probability (%) on the Y-axis over time in months on the X-axis for two patient groups: Fulvestrant plus Ribociclib and Fulvestrant plus Placebo. The chart includes a legend, censored data points, and a table indicating the number of patients at risk over time for each group.*

FDA Label Image

Fulvestrant-fig-2 (Fulvestrant Fig 2)

An instructional illustration showing a hand holding a syringe with an arrow indicating how to pull back the plunger, and a close-up diagram of a two-part vial or syringe cap assembly with labeled parts A, B, and C for proper removal or attachment.*

FDA Label Image

Fulvestrant-fig-3 (Fulvestrant Fig 3)

An instructional illustration showing two hands holding a syringe and an ampule or vial, demonstrating preparation or drawing of an injection. The image relates to proper technique for preparing an intramuscular injection of Fulvestrant.*

FDA Label Image

Fulvestrant-fig-4 (Fulvestrant Fig 4)

An instructional diagram showing the proper use of an injection syringe with a needle, including a close-up detail of the needle on the left side of the image. The illustration likely demonstrates how to prepare the syringe for an intramuscular injection.*

FDA Label Image

Fulvestrant-fig-5 (Fulvestrant Fig 5)

An instructional illustration showing a hand holding and preparing a syringe, with an arrow indicating the movement, likely depicting how to draw medication from a vial or ampule for injection.*

FDA Label Image

Fulvestrant-fig-6 (Fulvestrant Fig 6)

A line graph showing Progression Free Survival in the ITT Population for Fulvestrant 250 mg and 500 mg dosages. The y-axis indicates the proportion of patients progression free, and the x-axis shows time in months up to 45 months. The graph includes a risk table listing the number of patients at risk for each dosage group over time.*

FDA Label Image

Fulvestrant-fig-7 (Fulvestrant Fig 7)

A survival curve graph comparing the proportion of patients alive over time (months) between two dosages of Fulvestrant: 500 mg and 250 mg. The x-axis represents time in months up to 80, and the y-axis shows the proportion of patients alive ranging from 0 to 1. The graph includes tick marks for censored observations and a table of patients at risk for each dosage at various time points.*

FDA Label Image

Fulvestrant-fig-8 (Fulvestrant Fig 8)

A Kaplan-Meier survival curve showing the probability of progression-free survival (PFS) over 36 months for two treatment groups: Fulvestrant 500 mg and Anastrozole 1 mg. The X-axis represents time from randomisation in months, and the Y-axis represents the probability of PFS, with a table below indicating the number of patients at risk at different time points for each treatment group.*

FDA Label Image

Fulvestrant-fig-9 (Fulvestrant Fig 9)

A Kaplan-Meier curve showing progression-free survival probability (%) over time in months for two groups: Fulvestrant plus palbociclib (solid line) and Fulvestrant plus placebo (dashed line). The plot includes numbers of patients at risk at various time points for each group, illustrating survival trends over 14 months.*

FDA Label Image

Fulvestrant Carton 250 mg (Fulvestrant Spl Carton)

Packaging label for Fulvestrant Injection 250 mg/5 mL (50 mg/mL) by BluePoint Laboratories. This carton contains two single-dose prefilled syringes, each with 250 mg/5 mL. The label specifies intramuscular use only and provides storage instructions to refrigerate at 2° to 8°C and protect from light. Directions for use and safety information are included, along with manufacturer details and barcode.*

FDA Label Image

Fulvestrant Label 250 mg (Fulvestrant Spl Pfs)

Label for Fulvestrant Injection 250 mg per 5 mL (50 mg/mL) intramuscular injection, presented as prefilled syringes. The label includes administration instructions, lot and expiration date fields, and is labeled for BluePoint Laboratories. Manufactured by Alembic Pharmaceuticals Limited, India.*

FDA Label Image

Fulvestrant-structure (Fulvestrant Structure)

Chemical structure of the active ingredient Fulvestrant, showing the molecular framework including hydroxyl groups and a sulfonyl-linked trifluoromethylated alkyl side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.